A Phase 3 interventional study of 2 DAA and RBV in HCV, Hepatitis C Infection and Genotype 4, sponsored by AbbVie. Completed. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2021-07-30.
Sponsored by AbbVie · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 174 studies testing ribavirin in Hepatitis C — none open to participants now, 1 under way, none of them phase 3. Ribavirin · Hepatitis C.
Among the 174 studies testing ribavirin in Hepatitis C, this one is the 50th largest by enrollment, is one of 17 that started in 2014, is one of 56 in phase 3, and was the 134th registered.
1,744 studies on the registry are indexed under Hepatitis C; 98 are open to participants now.
Browse Hepatitis C studies →None of the 174 studies testing ribavirin in Hepatitis C is open now. The open studies under Hepatitis C, anywhere →
Ribavirin: first FDA approval 1985 (VIRAZOLE), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →
Of the 56 Hepatitis C studies recruiting now, 43 (77%) set no upper age limit and 6 (11%) stop at 75 or younger; 10 take children under 18; 26 take healthy volunteers.
This study: 18 Years to 99 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
174 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 61 · Phase 3 64 · Phase 4 44
First in 1997; this study’s year is marked. 17 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 160 is above the median of 73 across 1,224 interventional studies indexed under Hepatitis C.
Median enrollment 78 across the 174 interventional studies. Of the 158 that completed or were terminated, 79 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
84 of 174 have an industry lead sponsor. The 10 most frequent:
AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.
Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.
90 studies in Hepatitis C by AbbVie: 1 open now, 1 under way, none of them phase 3. Of 88 finished, 71 (81%) have results posted.
Among the 90 studies in Hepatitis C by AbbVie, this one is the 31st largest by enrollment of the 74 interventional ones that give a count, is one of 14 that started in 2014, is one of 46 in phase 3, and was the 38th registered.
AbbVie’s Hepatitis C studies by the year they started, since 2008.
None of the studies under way reaches primary completion within a year.
Among the 174 studies testing ribavirin in Hepatitis C, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AbbVie’s 90 in Hepatitis C:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study evaluates the efficacy and safety of ABT-450/r/ABT-267 with RBV in treatment-naive and treatment-experienced HCV GT4 subjects without or with compensated cirrhosis.
Non-cirrhotic subjects were directly enrolled into Arm A. Cirrhotic subjects were randomized to either Arm B (12 weeks of treatment) or Arm C (24 weeks of treatment).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subjects must meet one of the following:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ABT-450/r/ABT-267 (paritaprevir/ritonavir/ombitasvir; 2 direct acting antiviral agent \[DAA\]) plus Ribavirin (RBV) for 12 weeks in treatment-naïve and treatment-experienced (with pegylated interferon and ribavirin) participants without cirrhosis.
Drug: 2 DAA · Drug: RBV
ABT-450/r/ABT-267 plus RBV for 12 weeks in treatment-naïve and treatment-experienced (with pegylated interferon and ribavirin) participants with compensated cirrhosis.
Drug: 2 DAA · Drug: RBV
ABT-450/r/ABT-267 plus RBV for 24 weeks in treatment-naïve and treatment-experienced (with pegylated interferon and ribavirin) participants with compensated cirrhosis.
Drug: 2 DAA · Drug: RBV
ABT-450/r/ABT-267 tablets
Ribavirin tablets
Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12) in Each Treatment Arm
SVR12 was defined as hepatitis C virus ribonucleic acid (HCV RNA) level less than the lower limit of quantification (\< LLOQ) 12 weeks after the last dose of study drug.
Time frame: 12 weeks after last dose
Number of Participants With Adverse Events
An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. The investigator assessed the relationship of each event to the use of study drug as either reasonable possibility or no reasonable possibility. A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the subject and may require medical or surgical intervention to prevent any of the outcomes listed above. Treatment-emergent events (TEAEs/TESAEs) are defined as any event that began or worsened in severity after the first dose of study drug. For more details on adverse events please see the Adverse Event section.
Time frame: Screening until 30 days after last dose
Percentage of Participants With On-treatment Virologic Failure in Each Treatment Arm
On-treatment virologic failure was defined as quantifiable HCV RNA throughout the entire treatment period with at least 6 weeks of treatment, confirmed HCV RNA greater than the LLOQ after previously having unquantifiable HCV RNA, or a confirmed increase from nadir of at least one log10 in HCV RNA during treatment.
Time frame: Up to 12 or 24 weeks after first dose
Percentage of Participants With Post-treatment Relapse Within 12 Weeks Following End of Treatment in Each Arm
Post-treatment relapse was defined as defined as confirmed HCV RNA \> LLOQ between the end of treatment and 12 weeks after the last dose of study drug among participants who completed treatment with HCV RNA \< LLOQ at the end of treatment.
Time frame: Up to 12 weeks after first dose
Safety population: All participants who received at least one dose of study drug.
| Milestone | Arm A | Arm B | Arm C |
|---|---|---|---|
| Started | 100 | 31 | 29 |
| Completed | 94 | 29 | 27 |
| Not completed | 6 | 2 | 2 |
| Withdrew: Adverse event | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 4 | 1 | 1 |
| Withdrew: Lost to follow-up | 1 | 1 | 1 |
SVR12 was defined as hepatitis C virus ribonucleic acid (HCV RNA) level less than the lower limit of quantification (\< LLOQ) 12 weeks after the last dose of study drug.
| percentage of participants | Arm A | Arm B | Arm C |
|---|---|---|---|
| Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12) in Each Treatment Arm | 94.0 (87.5 to 97.2) | 96.8 (83.8 to 99.4) | 93.1 (78.0 to 98.1) |
An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. The investigator assessed the relationship of each event to the use of study drug as either reasonable possibility or no reasonable possibility. A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the subject and may require medical or surgical intervention to prevent any of the outcomes listed above. Treatment-emergent events (TEAEs/TESAEs) are defined as any event that began or worsened in severity after the first dose of study drug. For more details on adverse events please see the Adverse Event section.
| Participants | Arm A | Arm B | Arm C |
|---|---|---|---|
| Number of Participants With Adverse Events | 80 | 26 | 25 |
On-treatment virologic failure was defined as quantifiable HCV RNA throughout the entire treatment period with at least 6 weeks of treatment, confirmed HCV RNA greater than the LLOQ after previously having unquantifiable HCV RNA, or a confirmed increase from nadir of at least one log10 in HCV RNA during treatment.
| percentage of participants | Arm A | Arm B | Arm C |
|---|---|---|---|
| Percentage of Participants With On-treatment Virologic Failure in Each Treatment Arm | 1.0 (0.2 to 5.4) | 3.2 (0.6 to 16.2) | 3.4 (0.6 to 17.2) |
Post-treatment relapse was defined as defined as confirmed HCV RNA \> LLOQ between the end of treatment and 12 weeks after the last dose of study drug among participants who completed treatment with HCV RNA \< LLOQ at the end of treatment.
| percentage of participants | Arm A | Arm B | Arm C |
|---|---|---|---|
| Percentage of Participants With Post-treatment Relapse Within 12 Weeks Following End of Treatment in Each Arm | 3.1 (1.0 to 8.6) | 0.0 (0.0 to 11.4) | 0.0 (0.0 to 12.1) |
Collected over Treatment-emergent adverse events (TEAEs) and serious adverse events (TESAEs) were collected from the time of study drug administration until 30 days after the last dose of study drug (up to 28 weeks).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arm A | — | 2/100 (2%) | 79/100 (79%) |
| Arm B | — | 0/31 (0%) | 24/31 (77.4%) |
| Arm C | — | 2/29 (6.9%) | 25/29 (86.2%) |
| Event | Arm A | Arm B | Arm C |
|---|---|---|---|
| OESOPHAGEAL VARICES HAEMORRHAGEGastrointestinal disorders | 0/100 | 0/31 | 1/29 |
| BILE DUCT STONEHepatobiliary disorders | 0/100 | 0/31 | 1/29 |
| CHOLECYSTITIS ACUTEHepatobiliary disorders | 0/100 | 0/31 | 1/29 |
| APNOEARespiratory, thoracic and mediastinal disorders | 1/100 | 0/31 | 0/29 |
| DEEP VEIN THROMBOSISVascular disorders | 1/100 | 0/31 | 0/29 |
| Event | Arm A | Arm B | Arm C |
|---|---|---|---|
| HEADACHENervous system disorders | 41/100 | 9/31 | 10/29 |
| FATIGUEGeneral disorders | 35/100 | 9/31 | 11/29 |
| COUGHRespiratory, thoracic and mediastinal disorders | 6/100 | 4/31 | 9/29 |
| PRURITUSSkin and subcutaneous tissue disorders | 23/100 | 4/31 | 9/29 |
| ABDOMINAL PAIN UPPERGastrointestinal disorders | 19/100 | 2/31 | 3/29 |
| DYSPEPSIAGastrointestinal disorders | 17/100 | 4/31 | 5/29 |
| NAUSEAGastrointestinal disorders | 7/100 | 2/31 | 5/29 |
| INSOMNIAPsychiatric disorders | 9/100 | 2/31 | 5/29 |
| CHROMATURIARenal and urinary disorders | 1/100 | 0/31 | 5/29 |
| ANAEMIABlood and lymphatic system disorders | 8/100 | 2/31 | 4/29 |
| Age, Continuous(years) | Arm A | Arm B | Arm C | Total |
|---|---|---|---|---|
| Mean | 48.6 ± 13.14 | 57.3 ± 6.48 | 55.8 ± 8.02 | 51.6 ± 11.91 |
| Sex: Female, Male(Participants) | Arm A | Arm B | Arm C | Total |
|---|---|---|---|---|
| Female | 30 | 2 | 7 | 39 |
| Male | 70 | 29 | 22 | 121 |
No study locations are listed for this record.
The record gives a start of Nov 2014, a primary completion of Aug 2016 and a completion of Aug 2016. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2017, 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ribavirin